Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 ?50%

Basit Öğe Kaydı
dc.contributor.authorSezer, A.
dc.contributor.authorGogishvili, M.
dc.contributor.authorBentsion, D.
dc.contributor.authorKılıçkap, S.
dc.contributor.authorLowczak, A.
dc.contributor.authorGümüş, M.
dc.contributor.authorGladkov, O.
dc.date.accessioned2025-05-10T19:42:51Z
dc.date.issued2019
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstract[No abstract available]
dc.identifier.doi10.1016/j.jtho.2019.08.1345
dc.identifier.endpageS638
dc.identifier.issn1556-0864
dc.identifier.issn1556-1380
dc.identifier.issue10
dc.identifier.scopusqualityQ1
dc.identifier.startpageS638
dc.identifier.urihttps://doi.org/10.1016/j.jtho.2019.08.1345
dc.identifier.urihttps://hdl.handle.net/20.500.14730/10398
dc.identifier.volume14
dc.identifier.wosWOS:000492162203260
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.ispartofJournal of Thoracic Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.subjectnon-small-cell lung cancer
dc.subjectanti-PD-1
dc.subjectcemiplimab
dc.titleCemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 ?50%
dc.typeConference Object

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
10398.pdf
Boyut:
165.96 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu